Cerus Corporation

University of California

The United States of America As Represented by the Department of Health

Cetus Corporation

Steritech, Inc.

Hoffmann-la Roche Inc.

Henry Rapoport

Susan Wollowitz

Stephen T Isaacs

Hans Peter Spielmann

Aileen Nerio

Corey H Levenson

Clinton D Snyder

John E Hearst

Dwight D Weller

Danute E Nitecki

Richard D Gless

Lois Aldwin

David F Mark

Margaret Moreland

Irwin Braude

Randy B Barber

Che-Kun J Shen

Stephen Isaacs

Kary B Mullis

Tae Bo Sim

David N Cook

Adonis Stassinopoulos

Edward L Sheldon, Iii

Jan Matejovic

John E Merritt

Per Sauerberg

William Alexander Denny

Robert M Watson

Thomas F Buckley

Dean R Bender

Jeffrey M Dener

Richard D Cless

Lin-hau Zhang

Frank S Gibson

Psoralen compound compositions are synthesized which have substitutions on the 4, 4&prime;, 5&prime;, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.

Compounds for the photodecontamination of pathogens in blood

Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods may be used to treat materials intended for in vitro or in vivo use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form breakdown products. The degradation reaction is preferably slower than the reaction with nucleic acid.

Frangible compounds for pathogen inactivation

Method for photodecontamination of pathogens in blood using 5'-primary aminopsoralens

The present invention includes compositions comprising new psoralens with either a or primary amino substituent and a blood product that is suitable for in vivo use. The compositions are useful for the inactivation of pathogens in blood products such as platelets and plasma.

Psoralen compounds

Psoralen compounds are synthesized which have substitutions on the 4, 4&prime;, 5&prime;, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, use of 5&prime;-primary aminoalkyl psoralens to inactivate pathogens in platelets is disclosed.

5&prime;-primary aminoalkyl psoralen compositions with platelets

Psoralen compounds are synthesized which have substitutions on the 4, 4&prime;, 5&prime;, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.

Methods for photodecontamination of pathogens in blood

Amino acids are derivatized for use in peptide synthesis by conversion to N-carboxyanhydrides that are N-protected by either a trityl or a phenylfluorenyl group.

N-trityl and N-phenylfluorenyl carboxyanhydrides of amino acids

Amino acids are derivatized for use in peptide synthesis by conversion to N-carboxyanhydrides that are N-proected by either a trityl or a phenylfluorenyl group.

Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.

4'-primary aminopsoralen and platelet compositions

Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic add of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular compounds with primary aminoalkyl substitutions on the 4' or 5' positions of psoralen are used to inactivate pathogens in blood products such as platelets.

Method for inactivation of pathogens in platelets using 4' and 5'

Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, 4' and 5' primary aminoalkyl psoralens are photoactivated in platelet preparations to inactivate pathogens.

Method for the photoactivation of 4' and 5' primary aminoalkyl psoralens

Psoralen compound compositions are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.

Method for the photo-decontamination of pathogens in blood using

Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention compemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, 5'-primary amino psoralens are photoactivated in order to inactivate pathogens in biological fluids.

Method of inactivating pathogens in biological fluids using

Growing community of inventors

Berkeley, CA, United States of America

Henry Rapoport